Terms: = Ovarian cancer AND BCL3, P20749, 602, ENSG00000069399, D19S37, BCL4 AND Prognosis
4 results:
1. The levels of soluble cMET ectodomain in the blood of patients with ovarian cancer are an independent prognostic biomarker.
Klotz DM; Link T; Goeckenjan M; Wimberger P; Kuhlmann JD
Mol Oncol; 2021 Sep; 15(9):2491-2503. PubMed ID: 33690968
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic Value of Focal Adhesion Kinase (FAK) in Human Solid Carcinomas: A Meta-Analysis.
Zeng XQ; Li N; Ma LL; Tseng YJ; Zhao NQ; Chen SY
PLoS One; 2016; 11(9):e0162666. PubMed ID: 27637100
[TBL] [Abstract] [Full Text] [Related]
3. Therapy-related myeloid leukemia after treatment for epithelial ovarian carcinoma: an epidemiological analysis.
Vay A; Kumar S; Seward S; Semaan A; Schiffer CA; Munkarah AR; Morris RT
Gynecol Oncol; 2011 Dec; 123(3):456-60. PubMed ID: 21855120
[TBL] [Abstract] [Full Text] [Related]
4. [Studies on clinical usefulness of new tumor markers of ovarian cancer, CA54/61 and CA602--III. Measurement of serum samples from patients with various benign or malignant diseases].
Nozawa S; Udagawa Y; Sasaki H; Ito K; Akiya K; Terashima Y; Takamizawa H; Ohkura H; Fujimoto S; Hashimoto M
Gan To Kagaku Ryoho; 1994 May; 21(6):823-32. PubMed ID: 8185340
[TBL] [Abstract] [Full Text] [Related]
